01:48 , Mar 4, 2017 |  BioCentury  |  Finance

VCs need not apply

After sealing its second deal with Astellas Pharma Inc. (Tokyo:4503) last week, Affinivax Inc. says it can continue to build its pipeline without any venture money. Founded in 2014, the vaccine company has sustained itself...
04:42 , Mar 3, 2017 |  BC Week In Review  |  Company News

Affinivax, Astellas deal

Affinivax granted Astellas exclusive, worldwide rights to its lead vaccine candidate targeting...
21:28 , Feb 28, 2017 |  BC Extra  |  Company News

Affinivax grants Astellas rights to pneumococcal vaccine

Affinivax Inc. (Cambridge, Mass.) granted Astellas Pharma Inc. (Tokyo:4503) exclusive, worldwide rights to its lead vaccine candidate targeting...
07:00 , Aug 8, 2016 |  BioCentury  |  Finance

Manufacturing gateway

An $8 million equity investment in Just Biotherapeutics Inc. could give the Bill & Melinda Gates Foundation and its biotech partners access to a GMP facility designed to lower R&D and manufacturing costs for biologics....
08:00 , Nov 16, 2015 |  BC Week In Review  |  Company News

Affinivax, Nosocomial Vaccine deal

Nosocomial Vaccine (NVC) partnered with Affinivax to develop vaccines to prevent nosocomial infections. The collaboration will utilize Affinivax’s Multiple Antigen Presentation System (MAPS) vaccine platform to develop the bacterial nosocomial infection vaccines. NVC will provide...
08:00 , Feb 23, 2015 |  BC Week In Review  |  Company News

Affinivax, PATH deal

Affinivax and PATH partnered to develop Affinivax’s vaccine candidate to prevent Streptococcus pneumoniae infections. The vaccine was developed using Affinivax’s multiple antigen presenting system (MAPS) technology. PATH will provide funding for development, preclinical testing and...
08:00 , Feb 5, 2015 |  BC Innovations  |  Finance

PPPs holding steady

BioCentury's annual analysis of public-private partnerships and early stage venture financing activity shows that the model of using PPPs to foster academic innovation is holding fast, and that academia is an active driver behind the...
08:00 , Nov 3, 2014 |  BC Week In Review  |  Financial News

Affinivax completes venture financing

Affinivax Inc. , Cambridge, Mass.   Business: Infectious   Date completed: 2014-10-30   Type: Venture financing   Raised: $4 million   Investor: Bill & Melinda Gates Foundation  ...
08:00 , Nov 3, 2014 |  BioCentury  |  Emerging Company Profile

Affinivax: MAPS for vaccines

Affinivax Inc. is developing vaccines for bacterial infections that it says could provide universal protection regardless of disease serotype and be more immunogenic, cheaper and less complex to manufacture than traditional subunit conjugate vaccines. The...